经皮冠状动脉介入治疗急性冠脉综合征患者氯吡格雷的成本-效果:一项系统评价方案。

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES
Saba Abidi, Anoop Kumar, Shridhar Dwivedi, Vinod Sharma, Sushama Talegaonkar, Denny John
{"title":"经皮冠状动脉介入治疗急性冠脉综合征患者氯吡格雷的成本-效果:一项系统评价方案。","authors":"Saba Abidi, Anoop Kumar, Shridhar Dwivedi, Vinod Sharma, Sushama Talegaonkar, Denny John","doi":"10.11124/JBIES-24-00390","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This systematic review will assess the cost-effectiveness of clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).</p><p><strong>Introduction: </strong>Antiplatelet drugs, including clopidogrel, ticagrelor, prasugrel, and aspirin, are crucial in managing ACS, preventing ischemia, and ultimately, death in PCI patients. Clopidogrel is the main treatment for those who have undergone PCI, used either alone or with aspirin. The incidence of ACS is rising globally, and is a major cause of premature death for millions. ACS management involves continuous medical therapy and costly procedures such as PCI, significantly straining health care resources.</p><p><strong>Inclusion criteria: </strong>Studies will be eligible for inclusion if they report on the cost-effectiveness of clopidogrel in patients with ACS compared with other antiplatelet drugs.</p><p><strong>Methods: </strong>This systematic review will adhere to the JBI methodology guidelines for systematic reviews of economic evaluation evidence. A preliminary search was conducted of MEDLINE (PubMed) using MeSH terms. Two independent reviewers will screen records at the title/abstract level, followed by full-text screening. Two reviewers will then assess methodological quality and extract data as per JBI guidelines. The JBI Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the included studies. The cost-effectiveness measures will be incremental cost, incremental cost per quality-adjusted life year gained, or incremental cost per disability-adjusted life year averted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to appraise the certainty of economic evidence, such as using resources and expenditure, for incorporating the results into the decision-making process.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024504614.</p>","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review protocol.\",\"authors\":\"Saba Abidi, Anoop Kumar, Shridhar Dwivedi, Vinod Sharma, Sushama Talegaonkar, Denny John\",\"doi\":\"10.11124/JBIES-24-00390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This systematic review will assess the cost-effectiveness of clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).</p><p><strong>Introduction: </strong>Antiplatelet drugs, including clopidogrel, ticagrelor, prasugrel, and aspirin, are crucial in managing ACS, preventing ischemia, and ultimately, death in PCI patients. Clopidogrel is the main treatment for those who have undergone PCI, used either alone or with aspirin. The incidence of ACS is rising globally, and is a major cause of premature death for millions. ACS management involves continuous medical therapy and costly procedures such as PCI, significantly straining health care resources.</p><p><strong>Inclusion criteria: </strong>Studies will be eligible for inclusion if they report on the cost-effectiveness of clopidogrel in patients with ACS compared with other antiplatelet drugs.</p><p><strong>Methods: </strong>This systematic review will adhere to the JBI methodology guidelines for systematic reviews of economic evaluation evidence. A preliminary search was conducted of MEDLINE (PubMed) using MeSH terms. Two independent reviewers will screen records at the title/abstract level, followed by full-text screening. Two reviewers will then assess methodological quality and extract data as per JBI guidelines. The JBI Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the included studies. The cost-effectiveness measures will be incremental cost, incremental cost per quality-adjusted life year gained, or incremental cost per disability-adjusted life year averted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to appraise the certainty of economic evidence, such as using resources and expenditure, for incorporating the results into the decision-making process.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024504614.</p>\",\"PeriodicalId\":36399,\"journal\":{\"name\":\"JBI evidence synthesis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JBI evidence synthesis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11124/JBIES-24-00390\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-24-00390","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:本系统综述将评估氯吡格雷在急性冠脉综合征(ACS)患者行经皮冠状动脉介入治疗(PCI)的成本-效果。简介:抗血小板药物,包括氯吡格雷、替格瑞、普拉格雷和阿司匹林,在控制ACS、预防缺血和最终预防PCI患者死亡方面至关重要。氯吡格雷是接受PCI治疗的患者的主要治疗方法,可单独使用或与阿司匹林合用。ACS的发病率在全球范围内呈上升趋势,是数百万人过早死亡的主要原因。ACS的管理涉及持续的药物治疗和昂贵的手术,如PCI,严重紧张的卫生保健资源。纳入标准:如果研究报告氯吡格雷与其他抗血小板药物相比在ACS患者中的成本-效果,则符合纳入标准。方法:本系统评价将遵循JBI方法指南对经济评价证据进行系统评价。使用MeSH词对MEDLINE (PubMed)进行初步检索。两位独立审稿人将在标题/摘要级别对记录进行筛选,然后进行全文筛选。然后,两名审稿人将根据JBI指南评估方法质量并提取数据。经济评价的JBI优势排名矩阵将用于总结和比较纳入的研究。成本效益措施将是增量成本,每获得质量调整生命年的增量成本,或每避免残疾调整生命年的增量成本。将使用建议分级、评估、发展和评价(GRADE)方法来评价经济证据的确定性,例如利用资源和支出,以便将结果纳入决策过程。系统评价注册:PROSPERO CRD42024504614。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cost-effectiveness of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review protocol.

Objective: This systematic review will assess the cost-effectiveness of clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

Introduction: Antiplatelet drugs, including clopidogrel, ticagrelor, prasugrel, and aspirin, are crucial in managing ACS, preventing ischemia, and ultimately, death in PCI patients. Clopidogrel is the main treatment for those who have undergone PCI, used either alone or with aspirin. The incidence of ACS is rising globally, and is a major cause of premature death for millions. ACS management involves continuous medical therapy and costly procedures such as PCI, significantly straining health care resources.

Inclusion criteria: Studies will be eligible for inclusion if they report on the cost-effectiveness of clopidogrel in patients with ACS compared with other antiplatelet drugs.

Methods: This systematic review will adhere to the JBI methodology guidelines for systematic reviews of economic evaluation evidence. A preliminary search was conducted of MEDLINE (PubMed) using MeSH terms. Two independent reviewers will screen records at the title/abstract level, followed by full-text screening. Two reviewers will then assess methodological quality and extract data as per JBI guidelines. The JBI Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the included studies. The cost-effectiveness measures will be incremental cost, incremental cost per quality-adjusted life year gained, or incremental cost per disability-adjusted life year averted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to appraise the certainty of economic evidence, such as using resources and expenditure, for incorporating the results into the decision-making process.

Systematic review registration: PROSPERO CRD42024504614.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JBI evidence synthesis
JBI evidence synthesis Nursing-Nursing (all)
CiteScore
4.50
自引率
3.70%
发文量
218
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信